Wockhardt reported a consolidated net profit attributable to equity shareholders of ₹106 crore for the quarter ended June 30, 2026 (Q1FY27), marking a significant turnaround from a net loss of ₹90 crore in the corresponding period last year. The pharmaceutical company’s revenue from operations grew by 25.9% year-on-year to ₹929 crore, driven by improved operating efficiency and higher top-line momentum. The Board of Directors approved the unaudited financial results on August 10, 2026, following a limited review by statutory auditors M S K C & Associates LLP.

Financial Performance Overview

Wockhardt’s total income for the quarter stood at ₹960 crore, comprising ₹929 crore from operations and ₹31 crore from other income. This compares to a total income of ₹758 crore in Q1FY26, where operational revenue was ₹738 crore. The company managed its expenses effectively, with total expenses amounting to ₹844 crore, down slightly from ₹843 crore in the previous quarter but significantly lower relative to revenue compared to the prior year.

The key driver of profitability was the expansion in operating margins. While the company incurred a loss before exceptional items and tax of ₹12 crore in Q1FY26, it achieved a profit before tax of ₹116 crore in Q1FY27. Tax expenses for the quarter included a current tax charge of ₹7 crore and a deferred tax charge of ₹2 crore, resulting in the final net profit figure.

Standalone Results

On a standalone basis, Wockhardt reported a net profit after tax of ₹107 crore for Q1FY27, an increase from ₹69 crore in Q1FY26. Standalone revenue from operations rose to ₹561 crore from ₹413 crore in the same period last year, reflecting strong domestic performance. Other income decreased to ₹33 crore from ₹55 crore in the previous quarter, though it remained higher than the ₹25 crore recorded in Q1FY26.

Standalone total income was ₹594 crore, against total expenses of ₹487 crore. The company reported no tax expense for the quarter on a standalone basis. Earnings per share (basic) on a standalone basis were ₹6.62, compared to ₹4.25 in Q1FY26.

Key Operational Highlights

• Revenue Growth: Consolidated revenue increased by nearly 26% year-on-year, indicating robust demand across its pharmaceutical segments.
• Profitability Turnaround: The shift from a consolidated net loss of ₹90 crore to a profit of ₹106 crore highlights improved cost management and operational leverage.
• Auditor Review: The results were subjected to a limited review by M S K C & Associates LLP, Statutory Auditors of the Company, pursuant to Regulation 33 of the SEBI Listing Regulations.

What the Numbers Show

The significant improvement in profitability is primarily attributed to top-line growth outpacing expense inflation. While total expenses rose by 9.6% year-on-year, revenue surged by 25.9%, leading to a substantial widening of the pre-tax margin. The absence of major exceptional items in the current quarter, compared to a charge of ₹97 crore in Q1FY26, also contributed positively to the bottom line. The consistent performance across both standalone and consolidated figures suggests that the turnaround is broad-based rather than isolated to specific subsidiaries.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE049B01025/5e5bb7ab-79cc-4267-9052-276ab8fe58ba.pdf

Wockhardt Limited has published a newspaper advertisement regarding the addendum to the notice of its 27th Annual General Meeting (AGM), formally notifying shareholders of a revised schedule and enhanced disclosure requirements. The public notice was published on August 7, 2026, in Business Standard (All India English edition) and Lokmat (Chhatrapati Sambhajnagar edition). This step follows the company’s issuance of the addendum on August 5, 2026, which moved the AGM start time from 3:30 p.m. to 10:30 a.m. Indian Standard Time (IST) on Monday, August 10, 2026. The earlier timing aims to improve shareholder participation in the virtual meeting conducted via Video Conferencing (VC) or Other Audio Visual Means (OAVM).

The publication complies with Regulation 30 read with Schedule III (Part A Para A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The addendum serves as an integral part of the original AGM notice dated May 4, 2026, and supersedes any conflicting time references in the Annual Report for FY25-26. Shareholders are advised to log in at the new time to ensure they do not miss the commencement of proceedings.

Key Changes in the Addendum

The primary modification concerns the schedule of the virtual meeting. All other contents of the original AGM notice remain unchanged. The updated details are summarized below:

Related Party Transaction Disclosures

In addition to the time change, the addendum mandates an insertion into the Explanatory Statement for Item Nos. 5, 6, and 7 of the AGM notice. This insertion aligns with Industry Standards on "Minimum information to be provided to the Audit Committee and Shareholders for approval of Related Party Transactions." The added paragraph confirms that:

• The Audit Committee has received all relevant information regarding the proposed related party transactions.
• The Managing Director and Chief Financial Officer have certified that these transactions are in the interest of the company.
• The Audit Committee has reviewed and approved these transactions prior to their submission to the shareholders.

This disclosure aims to enhance transparency and provide shareholders with adequate information to make informed decisions on matters involving related parties.

Accessing the Documents

The addendum is being circulated electronically to members with registered email addresses. It is also available on the company’s website, alongside the original AGM notice and the Annual Report. Shareholders can access these documents via the National Securities Depository Limited (NSDL) e-voting portal as well as the BSE and NSE websites. Copies of the newspaper extracts are also hosted on the company’s official website.